# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Etzer Darout reiterates Terns Pharma (NASDAQ:TERN) with a Outperform and maintains $19 price target.
Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) ...
CEO Amy Burroughs Highlights Kogan's Leadership And Industry Knowledge As Key To Growth; Bryan Yoon To Stay Through Septemb...
- SEC Filing
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical compan...
HC Wainwright & Co. analyst Ed Arce reiterates Terns Pharma (NASDAQ:TERN) with a Neutral and maintains $5.5 price target.